Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Inhibitor”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05565378
What this trial is testing

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 351
Testing effectiveness (Phase 2)Ended earlyNCT00557596
What this trial is testing

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Who this might be right for
CarcinomaPancreas
Aegera Therapeutics 48
Not applicableStudy completedNCT04253080
What this trial is testing

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors

Who this might be right for
Cutaneous Melanoma
Assistance Publique - Hôpitaux de Paris 127
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626479
What this trial is testing

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 400
Testing effectiveness (Phase 2)Study completedNCT00882869
What this trial is testing

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Advanced Hepatocellular Carcinoma
Aegera Therapeutics 75
Large-scale testing (Phase 3)Not Yet RecruitingNCT06089382
What this trial is testing

Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Who this might be right for
Hepatocellular Carcinoma
Tongji Hospital 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626518
What this trial is testing

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 370
Large-scale testing (Phase 3)Study completedNCT03358472
What this trial is testing

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Who this might be right for
Head and Neck Cancer
Incyte Corporation 89
Testing effectiveness (Phase 2)Looking for participantsNCT06996782
What this trial is testing

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca 152
Large-scale testing (Phase 3)Study completedNCT04003636
What this trial is testing

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Who this might be right for
Biliary Tract Carcinoma
Merck Sharp & Dohme LLC 1,069
Testing effectiveness (Phase 2)Study completedNCT03910660
What this trial is testing

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Who this might be right for
Prostate CancerNeuroendocrine TumorsSmall Cell Carcinoma
BioXcel Therapeutics Inc 98
Large-scale testing (Phase 3)Ended earlyNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Large-scale testing (Phase 3)Not Yet RecruitingNCT06089369
What this trial is testing

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Who this might be right for
Hepatocellular Carcinoma
Tongji Hospital 360
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07740941
What this trial is testing

NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

Who this might be right for
Melanoma (Skin Cancer)Melanoma Stage Stage IIIBMelanoma Stage M1+1 more
UNC Lineberger Comprehensive Cancer Center 55
Testing effectiveness (Phase 2)Looking for participantsNCT06228066
What this trial is testing

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Who this might be right for
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT04997850
What this trial is testing

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectableTransarterial ChemoembolizationTyrosine Kinase Inhibitor+1 more
Xinrui Zhu，MD 142
Early research (Phase 1)Study completedNCT01062152
What this trial is testing

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Telik 19
Large-scale testing (Phase 3)WithdrawnNCT06513884
What this trial is testing

HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Who this might be right for
Oropharyngeal Squamous Cell Carcinoma Recurrent
Hookipa Biotech GmbH
Testing effectiveness (Phase 2)Study completedNCT04305041
What this trial is testing

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 100
Early research (Phase 1)Ended earlyNCT04155580
What this trial is testing

ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc. 68
Next Page